{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-012616","form_type":"8-K","ticker":"JYNT","cik":"0001612630","company_name":"JOINT Corp","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.190231+00:00","generated_at":"2026-05-24T21:20:11.524264+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"The Joint Corp reports Q4 revenue up 14%, 2025 guidance for lower EBITDA","bullets":["Q4 revenue from continuing operations $14.4M (+14% YoY); net income $986k vs loss $10.2M.","System-wide sales $145.2M (+9% Q4), comp sales 6%. Full-year sales $530.3M (+9%).","2025 guidance: system-wide sales $550-570M, consolidated adj EBITDA $10-11.5M vs $11.4M in 2024.","New franchised clinic openings expected 30-40 in 2025 vs 57 in 2024; refranchising of corp clinics ongoing.","Comp plan amended: CEO STIP max up to 125% base salary if EBITDA exceeds budget; CFO up to 62.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-012616","json":"https://secwatch.observer/filing/0001628280-25-012616.json","markdown":"https://secwatch.observer/filing/0001628280-25-012616.md","text":"https://secwatch.observer/filing/0001628280-25-012616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1612630/000162828025012616/0001628280-25-012616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1612630/000162828025012616/jynt-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:20:11.524264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}